Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ADRO]
Reports for Purchase
Showing records 1 - 20 ( 199 total )
Industry: Medical - Biomedical and Genetics
2Q20 Results; Awaiting Closing of Chinook Merger
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
KOL Call Highlights BION-1301''s Potential in IgAN
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Aduro Exits, Enter Chinook; Merger and New Focus Announced; Target to $3.75
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
1Q20 Results; Cash Strong Ahead of BION-1301 and ADU-S100 Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Important Data Still to Flow According to Relative Timelines
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
2019 Results; APRIL and STING Should Reignite Interest This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Merck Starts a Study, Aduro Cashes a $10M Check
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
STING Program Continues to Evolve at Novartis; Target Reduced to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department